The Positives
+ Record gross profit and NPAT. 1H21 revenue and gross profit were in line at 54%/51%, but NPAT and PATMI exceeded at 75% of our estimates. We attribute this to S$6.8mn of net fair value gains from its disposal of financial assets and lower-than-expected SG&A expenses. Permanent-staffing revenue grew 25.1%, underpinned by a 17.5% increase in revenue per placement YoY as HRnet filled more senior and niche positions that command higher remuneration packages. Flexible-staffing revenue rose by 31.9% on the back of a 47.1% YoY spike in the number of contractors hired to an all-time-high of 17,123 in June 2021. This was thanks to its Recruit First business expansion in 2019 and 2020 and clients’ preference for manpower flexibility amid business uncertainties.
+ Recovery in key markets. Singapore is HRnet’s largest revenue and gross-profit contributor. 1H21 gross profit in this market grew 31.1% YoY: flexible staffing +33.5% and permanent recruitment +25.0%. Gross profit in North Asia, comprising China, Hong Kong and Taiwan, was up 29.9% YoY: flexible staffing +57.6% and permanent recruitment +23.9%. Volume growth was notably strong for flexible staffing in Rest of Asia, particularly Malaysia and Indonesia, where gross profit surged 40.8%.
+ Strong hiring in healthcare sector. The healthcare and life-science sector which serves pharmaceutical firms, hospitals and vaccination centres contributed 26% to revenue in 1H21, up from 15% in 1H20. The hiring of vaccination nurses constituted about 2% of revenue. Although more than 70% of the Singapore population is now fully vaccinated, demand for medical staff is still expected to come through in various forms, such as more nurses in hospitals, social-distancing ambassadors and temperature scanners at the airport. As Singapore gradually reopens borders for vaccinated travellers and a third booster shot for better immunity is within sights, hiring in the healthcare sector is not expected to pull back in the near term.
The Negative
– Pandemic-related relief tapered off. Pandemic-related assistance dropped in 1H21, as government grants and subsidies declined S$1.7mn from S$7.9mn in 1H20. We expect pandemic-related assistance to diminish by end-FY21, leaving S$4-5mn of government grants from the Wage Credit Scheme. We believe that this scheme will continue to support HRnet’s bottom line, given that the scheme has been introduced and extended since 2013.
Outlook
As various Asian economies commence their recovery with the aid of vaccination programmes, pent-up demand from 2020’s hiring standstill is expected to unleash job openings and employment churns. Strong local employment is predicated on restricted border movements. Still a market leader in Singapore in revenue and profits, we remain optimistic that HRnet will be able to ride the rush for employment. While a continued recovery in the permanent recruitment of mid-level positions is contingent on a re-opening of the economies that HRnet operates in, flexible-staffing volume is expected to grow further as various sectors and organisations choose this option to avoid committing to permanent headcounts.
Maintain BUY with a higher TP of $1.05 from S$1.00.
We lift our FY21e revenue and gross profits by 1.8% and 1.1% on the back of higher-than-expected flexible-staffing contributions. FY21e NPAT and PATMI have been raised by 27.7%, after accounting for higher other income of S$10.4mn and lower SG&A expenses. The increase in other income comprises S$6.8mn of net fair value gains from its disposal of financial assets as well as an additional S$3.6mn of pandemic-related government grants.
After adjusting for the one-offs, our FY21e core PATMI increases by 8.8%. Accordingly, our TP climbs to S$1.05 from S$1.00. This is still set at 14x FY21e ex-cash P/E, HRnet’s historical 5-year high as we anticipate labour market recovery and potential M&As.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
